Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CBIO
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | BlackRock, Inc. | 2.08M | 5.6% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Dmitry Balyasny | 1.66M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Dames GP LLC | 1.66M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Balyasny Asset Management Holdings LP | 1.66M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Bam GP LLC | 1.66M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Balyasny Asset Management L.P. | 1.66M | 6.0% | SCHEDULE 13G/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Tomas Kiselak | 6.59M | 16.5% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Peter Harwin | 6.60M | 16.5% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Fairmount Healthcare Fund II L.P. | 6.59M | 16.5% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Fairmount Funds Management LLC | 6.59M | 16.5% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Tang Capital Partners III, Inc | 91,904 | 0.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Tang Capital Partners International, LP | 451,619 | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Tang Capital Partners, LP | 616,477 | 2.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Kevin Tang | 1.16M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Tang Capital Management, LLC | 1.16M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Dmitry Balyasny | 1.51M | 5.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Dames GP LLC | 1.51M | 5.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Balyasny Asset Management Holdings LP | 1.51M | 5.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Bam GP LLC | 1.51M | 5.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Balyasny Asset Management L.P. | 1.51M | 5.5% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Bong Y. Koh | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Nimish Shah | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | VHCP Management EG, LLC | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | VHCP Management III, LLC | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | VHCP Co-Investment Holdings III, LLC | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Venrock Healthcare Capital Partners III, L.P. | 2.67M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Ryan Wilder | 1.50M | 5.4% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Vestal Point Capital, LP | 1.50M | 5.4% | SCHEDULE 13G ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Abigail P. Johnson | 4.13M | 15.0% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | FMR LLC | 4.13M | 15.0% | SCHEDULE 13G/A ↗ |
| Dec 11, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Forbion Growth III Management B.V. | 1.68M | 6.1% | SCHEDULE 13G ↗ |
| Dec 11, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. | 1.68M | 6.1% | SCHEDULE 13G ↗ |
| Dec 11, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | ForGrowth III PA B.V. | 1.68M | 6.1% | SCHEDULE 13G ↗ |
| Dec 8, 2025 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Tomas Kiselak | 5.64M | 18.5% | SCHEDULE 13D/A ↗ |
| Dec 8, 2025 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Peter Evan Harwin | 5.64M | 18.5% | SCHEDULE 13D/A ↗ |
| Dec 8, 2025 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Fairmount Healthcare Fund II L.P. | 5.64M | 18.5% | SCHEDULE 13D/A ↗ |
| Dec 8, 2025 | SCHEDULE 13D/A (amended) | CBIO Crescent Biopharma, Inc. | Fairmount Funds Management LLC | 5.64M | 18.5% | SCHEDULE 13D/A ↗ |
| Oct 14, 2025 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | Jiaqiang Li | 1.43M | 10.3% | SCHEDULE 13G/A ↗ |
| Oct 14, 2025 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | 1Globe Capital LLC | 1.43M | 10.3% | SCHEDULE 13G/A ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Tang Capital Partners International, LP | 306,319 | 2.2% | SCHEDULE 13G ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Tang Capital Partners, LP | 393,681 | 2.8% | SCHEDULE 13G ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Kevin Tang | 700,000 | 5.0% | SCHEDULE 13G ↗ |
| Oct 9, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Tang Capital Management, LLC | 700,000 | 5.0% | SCHEDULE 13G ↗ |
| Aug 20, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | Jiaqiang Li | 896,712 | 6.5% | SCHEDULE 13G ↗ |
| Aug 20, 2025 | SCHEDULE 13G | CBIO Crescent Biopharma, Inc. | 1Globe Capital LLC | 896,712 | 6.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CBIO Crescent Biopharma, Inc. | William Arsani | 575,000 | 4.1% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 8:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances